



Press release 18 June 2026

### **Diamyd Medical announces update regarding interim CFO**

Diamyd Medical today announces that Anna Styruud, appointed interim CFO in Diamyd Medical, will not be able to start her position as previously communicated due to changes in her availability. A review to find a new successor to the CFO position has begun.

#### **About Diamyd Medical**

Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The Company's investigational drug candidate retogatein, based on recombinant GAD65, was evaluated in the Phase 3 DIAGNODE-3 trial in recent-onset type 1 diabetes. The Company has established a facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.

#### **For further information, please contact:**

Anders Essen-Möller, CEO

Phone: +46 705 51 06 79

E-mail: [anders.essen-moller@diamyd.com](mailto:anders.essen-moller@diamyd.com)

#### **Diamyd Medical AB (publ)**

Box 7349, SE-103 90 Stockholm, Sweden. Phone: +46 8 661 00 26

E-mail: [info@diamyd.com](mailto:info@diamyd.com) Org. nr: 556242-3797 Website: <https://www.diamyd.com>

The information was provided by the contact person above, for publication on 08.30 CET, June 18, 2026.